A PYMNTS Company

Several States Probe Crypto Trading Firm Genesis Global Capital

By  |  November 27, 2022
Several States Probe Crypto Trading Firm Genesis Global Capital

Several US state regulators are looking into whether crypto trading firm Genesis Global Capital may have violated securities laws, according to a report from Barron’s.
The report said that Alabama Securities Commission Director Joseph Borg indicated that his agency and several other states are involved in the investigations, which focus on whether Genesis and other companies persuaded residents of their states to invest in crypto securities without having the proper registrations. Borg did not name the other companies being investigated.
Neither Genesis nor the Alabama Securities Commission responded immediately to requests for comment.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Related: Senate Bill Would Offer Safe Harbor For Crypto Exchanges

    Earlier this week, Genesis confirmed it had hired an investment bank to explore its options, including bankruptcy, as it has struggled to recover from its exposure to collapsed crypto exchange FTX and before that to failed crypto hedge fund Three Arrows Capital.
    Genesis had spent much of November scrambling to raise fresh capital or reach a deal with creditors. The company’s institutional lending unit last week was forced to suspend redemptions and new loan originations. Genesis also previously disclosed that its derivatives unit had about $175 million in locked funds in its FTX trading account. As a result, parent company Digital Currency Group (DCG) opted to strengthen Genesis’ balance sheet with an equity infusion of $140 million.